证券之星消息，1月8日南向资金减持3500.0股讯飞医疗科技（02506.HK）。近5个交易日中，获南向资 金减持的有4天，累计净减持19.39万股。近20个交易日中，获南向资金减持的有11天，累计净减持21.55 万股。截至目前，南向资金持有讯飞医疗科技（02506.HK）372.87万股，占公司已发行普通股的 4.82%。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 讯飞医疗科技股份有限公司是一家主要从事提供人工智能赋能的医疗解决方案的中国公司。基层医疗服 务业务线由智医助理及慢病管理组成。医院服务业务线包括智慧医院解决方案和诊疗助理。患者服务业 务线包括智慧医院患者服务与诊后管理（包括讯飞晓医App及小程序）、影像云平台以及医疗器械。区 域管理平台解决方案业务线包括智慧卫生解决方案和智慧医保。该公司主要在国内市场开展业务。 ...

证券之星消息，12月22日南向资金减持4.09万股讯飞医疗科技（02506.HK）。近5个交易日中，获南向 资金减持的有4天，累计净减持10.79万股。近20个交易日中，获南向资金增持的有14天，累计净增持 9.16万股。截至目前，南向资金持有讯飞医疗科技（02506.HK）397.86万股，占公司已发行普通股的 5.14%。 讯飞医疗科技股份有限公司是一家主要从事提供人工智能赋能的医疗解决方案的中国公司。基层医疗服 务业务线由智医助理及慢病管理组成。医院服务业务线包括智慧医院解决方案和诊疗助理。患者服务业 务线包括智慧医院患者服务与诊后管理（包括讯飞晓医App及小程序）、影像云平台以及医疗器械。区 域管理平台解决方案业务线包括智慧卫生解决方案和智慧医保。该公司主要在国内市场开展业务。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

西南证券发布研报称，中国医疗人工智能行业空间较大，政策推动行业快速发展；讯飞医疗科技 (02506)具备自研基座大模型，性能上限持续抬升。星火医疗大模型X1能够显著降低幻觉现象，提升推 理的正确性、专业性与可解释性；基于大模型和大数据技术平台，构建多元化GBC客户产品矩阵。首 次覆盖，建议关注。 西南证券主要观点如下： 基于大模型和大数据技术平台，构建多元化GBC客户产品矩阵 截至2024年底，公司已向超过7万家基层医疗机构提供产品和服务，业务覆盖全国30多个省份、670多个 区县，以及500多家等级医院，其中包含了中国百强医院中的40多家和十强医院中的7家。1)To G基层医 疗服务业务25H1收入增速52.3%；区域管理平台解决方案25H1收入增速178.1%：基层医疗服务+区域管 理平台解决方案是基本盘，基层医疗服务业务线主要由智医助理和慢病管理组成，区域管理平台解决方 案主要是由智慧卫生和智慧医保组成；2)To B业务25H1收入下滑10%：主要由于大模型持续更新。业务 包括智慧医院+AI诊疗助理，提升医疗服务能力与效率；3)To C业务25H1收入增速10%：包括影像云平 台+诊后管理+讯飞晓医+智 ...

Core Insights - China is a significant market for global medical AI solutions, benefiting from technological advancements, high-quality medical data accumulation, supportive national policies, and growing market demand, leading to rapid growth in AI applications in healthcare [1][4]. Market Size and Growth - The market size for medical AI solutions in China is projected to grow from 9.1 billion yuan in 2021 to 16.4 billion yuan in 2024, with L1 solutions increasing from 5.8 billion yuan to 9.4 billion yuan, L2 solutions from 3.3 billion yuan to 6.9 billion yuan, and L3 solutions at 0.1 billion yuan [1][4]. - By 2025, the market size is expected to reach 18.2 billion yuan, with L1 solutions at 9.8 billion yuan, L2 solutions at 7.8 billion yuan, and L3 solutions at 0.6 billion yuan [1][4]. Industry Definition and Applications - Medical AI solutions utilize AI technologies such as machine learning, deep learning, natural language processing, and big data analysis to enhance various medical processes, including diagnosis, treatment, drug development, and hospital management [2][3]. - The industry is evolving from L1 and L2 solutions, which provide supportive insights, to L3 and L4 autonomous agents capable of executing tasks independently [2][3]. Industry Development Status - The integration of general large model capabilities with medical knowledge bases is driving the transition of medical AI solutions towards higher levels of autonomy [3][4]. - The global market for medical AI solutions is expected to grow from 23.2 billion yuan in 2021 to 40 billion yuan in 2024, with L1 solutions increasing from 13.9 billion yuan to 21.1 billion yuan, L2 solutions from 9.3 billion yuan to 18.7 billion yuan, and L3 solutions at 0.2 billion yuan [4]. Industry Chain - The medical AI solutions industry chain includes upstream data supply, hardware providers (chips, servers), cloud services, operating systems, and algorithms, with midstream companies providing AI solutions and downstream applications in healthcare institutions, pharmaceutical companies, and individual patients [5]. Policy Environment - The Chinese government has prioritized the application of AI in healthcare, implementing policies to support AI in medical diagnosis, health management, and insurance regulation, which are expected to accelerate the development of AI in healthcare [5]. Competitive Landscape - The industry features a competitive landscape with local giants, vertical startups, and multinational companies. Key players include iFlytek Medical, Baidu, United Imaging, CloudWalk, Weining Health, and Mindray Medical [7]. - iFlytek Medical is a leading company in the AI healthcare sector, leveraging its large model to empower various healthcare stakeholders and has developed comprehensive AI solutions for hospitals and primary care institutions [9][11]. Revenue Structure of Key Players - iFlytek Medical reported a revenue of 299 million yuan in the first half of 2025, with contributions from various solutions: 84 million yuan from primary care solutions, 58 million yuan from regional solutions, 53 million yuan from hospital solutions, and 104 million yuan from patient management services [11]. - The company aims to build a robust B-end ecosystem to strengthen its commercial channels [9]. Future Trends - The development of the medical AI industry will be driven by a combination of technology, data, scenarios, and regulation, leading to a more mature, deeper, and broader market landscape [12].

Core Insights - The core viewpoint of the articles is that iFlytek Medical's recent bid win of 427.6 million yuan for a national AI application pilot base in healthcare signifies a breakthrough in the AI medical industry, which has been struggling with technology implementation and unclear profit models [1][10]. Group 1: Market Demand and Policy Support - The healthcare sector in China faces significant demand, with the average life expectancy reaching 79 years and over 141.36 million elderly individuals requiring health management in grassroots medical institutions by 2024 [1][3]. - The number of patient visits to grassroots medical institutions has increased by 230 million to 3.98 billion, highlighting a growing supply-demand imbalance in healthcare services [1]. - National policies aim for widespread application of intelligent assistance in grassroots diagnosis by 2027 and full coverage by 2030, with various provinces implementing AI support policies to promote technology penetration [3]. Group 2: Brand Value and Market Position - Winning the national project enhances iFlytek Medical's brand value by providing a "national endorsement," which strengthens its authority in the AI medical field [1][4]. - The project allows iFlytek Medical to transition from an "industry participant" to a "standard setter," addressing challenges like the lack of standards and data fragmentation in medical AI applications [4][9]. Group 3: Strategic Implementation and GBC Model - The project validates iFlytek Medical's GBC (Government, Business, Consumer) strategy, which integrates policy, business scale, and consumer demand to create a complete value chain [5][6]. - The G-end business serves as a foundational strategy, with the core product "Smart Medical Assistant" already covering 31 provinces and providing over 1.1 billion AI-assisted diagnoses [6][7]. - The project will enable the conversion of successful local experiences into nationwide standards, facilitating deeper penetration into B-end medical institutions and ultimately supporting C-end consumer growth [7][8]. Group 4: Technological Foundation and Competitive Edge - iFlytek Medical's AI model is the only fully domestically controlled medical model, outperforming competitors like GPT-5 in various capabilities, ensuring compliance with data security requirements [9]. - The technological strength not only meets G-end data security demands but also builds trust among C-end users regarding health data safety, which is crucial for long-term growth [9][10].

Core Insights - The announcement of a 427.6 million yuan bid by iFlytek Medical serves as a breakthrough for the AI healthcare industry, which has been struggling with "technological stagnation" and "unclear profit models" [1] - The project awarded to iFlytek Medical is a result of the convergence of policy direction, market demand, and technical strength, marking a significant recognition of the company's capabilities [1][3] Industry Demand - In 2024, the average life expectancy in China reached 79 years, with a significant increase in the elderly population requiring health management, particularly among those aged 65 and above, totaling 141.36 million [1] - The number of outpatient visits at grassroots medical institutions reached 3.98 billion, an increase of 230 million from the previous year, highlighting the growing demand for healthcare services [1] Brand Value and Recognition - The national-level project bid provides iFlytek Medical with a "national endorsement," enhancing its brand value and establishing it as a key player in the AI healthcare sector [1][3] - The project aligns with national goals to achieve widespread application of intelligent assistance in grassroots healthcare by 2027 and full coverage by 2030, further amplifying the brand's influence [3] Strategic Transition - The bid signifies a shift for iFlytek Medical from being an "industry participant" to a "standard setter," addressing challenges such as the lack of standards and data fragmentation in medical AI applications [4] - The company aims to develop a replicable "medical AI operating system" based on its extensive medical model and high-quality data platform [4] GBC Strategy Implementation - The successful bid validates iFlytek Medical's GBC (Government-Business-Consumer) strategy, which integrates policy, business, and consumer needs into a cohesive value chain [5] - The G-end business serves as a foundational strategy, with the company's core product "Smart Medical Assistant" already covering 31 provinces and providing over 1.1 billion AI-assisted diagnoses [6] B-end Market Penetration - iFlytek Medical has established deep collaborations with over 500 top-tier hospitals, facilitating the transition of proven solutions into standardized products that meet the digital transformation needs of various healthcare institutions [7] - The project is expected to significantly reduce procurement and validation costs for healthcare institutions, enhancing the company's competitive edge in the B-end market [7] C-end Business Growth - The aging population and rising chronic diseases have transformed proactive health management from an optional service to a necessity, driving demand for iFlytek Medical's consumer products [8] - The "iFlytek Xiaoyi APP" has achieved over 1.6 billion AI consultations and 26 million downloads, indicating strong user engagement and satisfaction [8] Technological Foundation - iFlytek's medical model is the only fully domestically produced and controllable model in the industry, surpassing competitors in various capabilities, thus ensuring data security and trust among users [9] - The company's technological strength is expected to be a core driver of long-term value growth, especially as policies continue to support grassroots healthcare [9] Conclusion - iFlytek Medical's value lies not only in its leading AI healthcare technology but also in its role as a core participant in the new infrastructure of AI healthcare, benefiting from policy incentives and market demand [10] - The ongoing project is set to enhance the company's data reserves and industry standards, accelerating the industrialization of AI healthcare infrastructure and driving significant growth in performance [10]

智通财经APP了解到，近日讯飞医疗（02506）以4.28亿元中标国家人工智能应用中试基地（医疗领域 基层卫生服务方向）软件服务项目。国家人工智能应用中试基地是为响应"人工智能+"政策，推动建设 一批产业链协同的"连接器"，技术成果转化的"加速器"以及优质应用落地的"孵化器"。此次讯飞医疗中 标，不仅彰显了公司技术实力，同时也意味着AI医疗赛道进入了政策驱动的加速期。作为此次项目的 承建方，更标志着该公司角色从行业参与者跃升为未来医疗AI国家标准的核心共建者。 今年以来，国家发改委协同多部门持续推动制造、医疗及交通等一批重点领域应用中试基地启动建设， 目前全国已有多地落地项目。AI+医疗赛道率先出发，11月4日，国家卫生健康委等五部门印发《关于 促进和规范"人工智能+医疗卫生"应用发展的实施意见》，深化推动AI在医疗领域的应用。 总的来说，2025年是"人工智能+"国家战略的推动元年，由政府牵头联合头部企业推动，而2026年将迎 来大规模应用浪潮。讯飞医疗具有行业多重领先优势，尤其是医疗AI大模型的断崖式领先，且构建了 GBC三大场景下AI产品矩阵，积累了庞大的用户群体，将使得该公司成为AI医疗赛道高成长的最 ...

Core Viewpoint - Recently, iFlytek Medical (02506) won a bid for a software service project worth 428 million yuan for the National Artificial Intelligence Application Pilot Base in the medical field, marking a significant step in the AI healthcare sector driven by policy support [1] Industry Overview - The National Development and Reform Commission, along with multiple departments, is actively promoting the establishment of pilot bases in key sectors such as manufacturing, healthcare, and transportation, with AI in healthcare leading the way [1] - The AI healthcare sector in China has experienced a compound annual growth rate (CAGR) of 33.8% from 2019 to 2023, and it is expected to continue leading the AI sector with a projected CAGR of 43% from 2023 to 2033, reaching a market size of 315.7 billion yuan [1] Company Impact - The recent bid win allows iFlytek Medical to solidify its leadership position in the industry by transitioning from "experimental exploration" to "industry definition" [2] - The company is positioned to benefit from the commercialization of AI medical technology, taking advantage of policy and market dividends [2] - iFlytek Medical's AI medical products have shown significant commercial success, with its core product "Zhi Yi Assistant" covering 31 provinces and serving over 250,000 grassroots doctors, providing over 1.1 billion diagnostic assists [3] Business Model Transformation - The focus on "grassroots health services" aligns with the most urgent needs in the healthcare system, supported by strong policy backing, with a goal of achieving full coverage of intelligent auxiliary applications by 2030 [3] - The recent project win shifts the company's business model from a single product delivery approach to a "model as a service" model, expected to enhance user stickiness and generate continuous service revenue [3] Future Outlook - 2025 is anticipated to be a pivotal year for the "Artificial Intelligence+" national strategy, with significant applications expected to emerge in 2026 [3] - iFlytek Medical's leading advantages in the industry, particularly in AI medical models, and its extensive user base position it as a major beneficiary in the high-growth AI healthcare sector [3][4]

在人工智能加速渗透千行百业的当下，AI在医疗领域的应用正迎来从"概念验证"向"产业落地"跨越的关 键拐点。近日，讯飞医疗科技(02506.HK)以4.28亿元中标国家人工智能应用中试基地(医疗领域基层卫生 服务方向)软件服务项目。作为国家"人工智能+"战略在基层医疗领域的重要落地项目，这一动向释放出 清晰的产业信号：具备"全栈自主技术"与"规模化应用场景"的能力的企业，正在完成从单一产品供应商 向行业基础设施建设者的角色跃迁。 此次讯飞医疗承担国家人工智能应用中试基地软件服务项目建设并非孤立的市场行为，而是政策导向与 技术成熟度共振的结果，折射出其在三大维度上的长期价值重估逻辑。 抢占标准高地：从"试验探索"迈向"行业定义" 国家人工智能应用中试基地的核心定位，在于解决大模型在垂直行业落地中面临的技术路径模糊、标准 缺失、场景验证复杂等共性难题。作为国务院《关于深入实施"人工智能+"行动的意见》中明确布局的 战略性基础设施，该平台被赋予"产业链协同创新连接器"和"技术成果转化加速器"等多重功能。讯飞医 疗此次作为承建方，标志着其角色已从行业参与者跃升为未来医疗AI国家标准的核心共建者。 此项目内容进一步强化了 ...

智通财经APP获悉，在人工智能加速渗透千行百业的当下，AI在医疗领域的应用正迎来从"概念验 证"向"产业落地"跨越的关键拐点。近日，讯飞医疗科技(02506)以4.28亿元中标国家人工智能应用中试 基地(医疗领域基层卫生服务方向)软件服务项目。作为国家"人工智能+"战略在基层医疗领域的重要落 地项目，这一动向释放出清晰的产业信号：具备"全栈自主技术"与"规模化应用场景"的能力的企业，正 在完成从单一产品供应商向行业基础设施建设者的角色跃迁。 商业模式进化：从"软件交付"到"模型即服务" 长期以来，医疗AI行业面临着商业模式单一、变现难的痛点。但讯飞医疗此次项目承担及过往运营数 据表明，其商业模式已实现关键进化。项目明确提出要建立"长效运营机制"，这意味着讯飞医疗正从传 统的软件项目一次性交付，向提供"大模型+数据+运营"的综合服务模式转型。 这一转型的可行性已在实际应用中得到验证。其核心产品"智医助理"已覆盖全国31个省市，服务超过25 万名基层医生，累计提供超11亿次辅助诊断。该系统的深度应用将基层医生的电子病历书写规范率从原 先不足40%显著提升至98%，这不仅是效率的提升，更体现了AI技术对基层医疗服务 ...